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1. Introduction  
Multiple myeloma (MM) is an heterogeneous plasma cell disorder of unknown etiology, 
with a wide range of clinical manifestations and a highly variable disease course. Survival 
varies from a few months to more than ten years. The disease is characterized by bone 
marrow (BM) infiltration by malignant plasma cells usually secreting a serum or urine 
monoclonal immunoglobulin (Ig) component. Progress has been made in the understanding 
of its pathogenesis including knowledge of BM microenvironment and of cellular and 
genetic factors implicated in disease mechanisms that are not uniform in all patients, thus 
partly explaining disease variability. Furthermore, based on these, new very performing 
biology-based treatment modalities have been developed and are either already available 
for patients or under evaluation.  
Prognostic factors (PFs) are needed to predict disease behavior and chemosensitivity to a 
given regimen in order to schedule the most efficient therapeutic approach. They are useful 
both at diagnosis and during disease course, because ongoing biologic transformations are 
taking place, related to further disease manifestations after response or resistance to 
treatment.  
Existing PFs can be divided into those expressing host characteristics, reflecting tumor load 
and associated with malignant plasma cell or BM microenvironment peculiarities.  
In the present context, existing knowledge regarding PFs and risk stratification-systems in 
MM, as well as their contribution in clinical practice, will be summarised. The need for re-
evaluation of some established concepts or guidelines as a consequence of the recent 
therapeutic advances, will be discussed. Focus will be made on symptomatic MM only, 
because this is the field where PFs and risk-stratification systems can contribute the most to 
a better disease management. 
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2. Prognostic factors evaluated before treatment 
Routine clinical and laboratory data assessed upon initial evaluation of newly diagnosed 
symptomatic MM patients include an important number of prognostic factors (Figure 1). 
Their ability to predict disease outcome has usually been established by retrospective 
clinical observations. Other important markers of disease behavior emerged more recently 
and resulted from a better knowledge of disease biology and from advances in laboratory 
technology. Because of the clinical importance of the information they provide, their 
evaluation became strongly recommended (Dimopoulos et al, 2011; Munshi et al, 2011).  
Medical history and physical examination
Age
PS
CBC + smears, 
Ca, Cr, 
SPE & IFE,
IgG, IgA, IgM
sFLC
BM smears & biopsy + morphology; 
PCs immunophenotype?
Karyotype, 
Skeletal survey, 
MRI
albumin, β2Μ, 
LDH
Workout At Diagnosis
Prognostic Factors
FISH of PCs for t(4;14), t(14;16), and del(17p)
GEP studies
Labelling Index
DNA copy number alteration by CGH/SNP array
Cytokines, Growth factors
 
PS: performance status, CBC: complete blood count, Ca: calcium, Cr: creatinine, Ig: immunoglobulin, PC: plasma 
cell, β2M: beta2-microglobulin, LDH: lactate dehydrogenase, sFLC: serum free light chain, MRI: magnetic 
resonance imaging, PET: positron emission tomography. FISH: fluorescence in situ hybridization, GEP: gene 
expression profiling, SNP: single nucleotide polymorphism  
Fig. 1. Recommended Workout And Prognostic Factors for MM Patients at Diagnosis.  
2.1 Prognostic factors expressing host characteristics 
2.1.1 Age 
The median age at the time of disease diagnosis is approximately 70 years and about 37% of 
patients are younger than 65 years (Durie et al, 2004; Durie et al, 2006). In several studies, 
younger age was associated with longer survival, both after conventional therapy and high-
dose treatment (Kyle R, 1995; Ludwig et al, 2008; Lenhoff et al, 2006). Indeed age is closely 
related to performance status and the presence of co-morbidities and consequently affects 
treatment choice. Elderly patients are weaker and present frequently other chronic diseases 
such as diabetes mellitus, increased blood pressure or cardiac diseases, thus eventually 
compromising the administration of simple drugs like corticosteroids that are an 
indispensable component of MM chemotherapy. They also develop more frequently than 
younger ones, post-therapy cytopenias and are more prone to infections. 
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2.1.2 Performance status 
Performance status (PS), assessed by the Eastern Cooperative Oncology Group (ECOG) or 
Karnofsky scale, has a considerable impact on patients’ outcome (Rajkumar & Buady, 2007). 
It was shown in a large unselected observational study that the adverse effect of PS on 
outcome was greater than any other single prognostic variable (Kyle et al, 2003). In addition, 
patients with a bad PS are not eligible for high dose treatment with autologous stem cell 
transplantation, independently of age.  
2.2 Prognostic factors derived from initial laboratory tests 
As already mentioned, during initial MM patients’ workout, routine haematology, 
biochemistry, immunology, histopathology, nuclear medicine and radiology tests are 
undertaken, both for diagnostic and prognostic purposes. Many of them are included in the 
Durie–Salmon staging system (Durie & Salmon, 1975) that has been for 30 years the 
standard risk-stratification model for MM patients and is still in use. It is a disease specific 
staging system that combines haemoglobin, calcium, paraprotein concentration and skeletal 
status by x-rays to separate MM patients into 3 distinct prognostic groups, further 
subdivided according to creatinine value. In addition, “disease mass” corresponding to each 
stage, was evaluated with complex mathematic calculations, thus suggesting that the 
aforementioned factors reflect to some extend tumour load, while renal status and extend of 
BM infiltration at aspiration’s site, do not. The major limitations of the Durie-Salmon staging 
were that evaluation of bone disease by x-rays is observer-dependent and that paraprotein 
quantification in light chain MM was evaluated by the amount of 24 hours proteinuria. 
2.2.1 Complete Blood Count (CBC) 
With regard to CBC assessed at diagnosis, anaemia is the most common finding. It confers 
an adverse prognosis without being an independent factor; it may reflect in part tumor 
burden although anaemia is mostly due to cytokines’ inhibitory activity and to impaired 
erythropoietin secretion or function. The other blood counts are usually normal. However, 
all kind of cytopenias (anemia, thrombocytopenia, neutropenia, lymphocytopenia), when 
observed, present a significant correlation with early death (Augustson et al, 2005). 
Thrombocytopenia in particular (Cavo et al, 1989) is a rare but powerful independent PF. 
2.2.2 Serum creatinine 
Renal impairment, due to excessive free light chain (FLC) secretion in urine, is associated 
with an adverse prognosis (Kyle et al, 2003; Drayson et al, 2005). Until 2001 FLC secretion 
was estimated by the amount of protein in the urine collected during 24 hours. During the 
past decade, a new assay was developed which allows precise quantification of serum free 
light chains (Bradwell, 2001). This method was shown useful for both diagnostic and 
prognostic purposes (see below in the current chapter).  
About 20% of patients have increased serum creatinine at the time of diagnosis, while 10% 
present acute renal failure and need haemodialysis. Their long term prognosis depends on 
renal recovery (Wirk et al, 2011), meaning that the correlation between increased creatinine 
and early death is mostly due to short term complications. Thus, the survival of patients 
with recovered kidney function is equivalent to those without renal failure.  
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2.2.3 Serum albumin 
Serum albumin, produced in the liver, regulates blood volume by maintaining blood 
compartment’s osmotic pressure and carries several molecules. The first reports of albumin 
being an important prognostic factor in MM patients came in the late 80s. (Simonsson et al, 
1988; Blade et al, 1989). These results were further validated later on (Kyle et al, 2003), 
leading to the incorporation of albumin into two staging systems, the SWOG (Jacobson et al, 
2003) and the currently widely used ISS (Greipp et al, 2005). 
2.2.4 Serum calcium 
Hypercalcemia is the most common metabolic disorder in MM patients. The main cause is 
bone destruction, which is induced by mediator proteins (RANKL, MIP-1a, DKK-1 and 
proinflammatory cytokines) produced by plasmacytes and stromal cells. Elevated serum 
calcium levels have a toxic effect on the kidneys, enhancing the damage caused by 
paraprotein. Inappropriate parathyroid hormone-like secretion may also contribute to 
increased calcium levels. 
The importance of elevated serum calcium as an adverse prognostic factor was recognized 
early and was incorporated into the Durie-Salmon staging system. In addition, calcium 
levels were shown to constitute an independent predictor of life quality (Wisløff et al., 2007).  
2.2.5 Imaging for the evaluation of bone disease 
X-rays of the spine, skull, chest, pelvis, humeri, and femora remain the standard to identify 
MM related bone lesions. Magnetic resonance imaging (MRI) is recommended to evaluate 
symptoms in patients with normal x-rays results and in all patients with findings suggesting 
the presence of solitary bone plasmacytoma. In Durie – Salmon staging, the presence of 
spontaneous fractures (bone scale 3) leads by itself to stage III disease, independently of any 
other factor. Accordingly, in a series of 158 consecutive MM patients from our department, 
those (24%) presenting spontaneous fractures at diagnosis had a worse outcome than the 
others (Figure 2), with a median disease specific survival of 38 versus 90 months (p=0.012).  
On the contrary, a recent study on the impact of bone lesions as evaluated by conventional 
radiography compared survival of patients with bone scale 0 and 1 (no lesions and diffuse 
osteoporosis) to the others, and failed to prove any difference (Li et al, 2010). 
Indeed, the evaluation of Durie-Salmon bone scale 0, 1 and 2 is much more subjective and 
depends on x-rays quality than scale 3 which involves the presence of fractures. In addition 
plain radiographs are relatively insensitive and can only demonstrate lytic bone disease 
when 30% or more of trabecular bone has been lost (Snapper I, 1971; Lecouvet et al, 1999). 
For all these reasons, Durie proposed in 2006, the incorporation into the system he had 
developed in the 70s, of MRI and positron emission tomography (PET) scan findings for the 
precise evaluation of lytic and other bone lesions (Durie BGM, 2006). The new staging was 
named Durie-Salmon Plus but was not widely adopted.  
MRI showed utility as a prognostic factor (Moulopoulos et al, 2005). The Hellenic MM 
working group evaluated 142 symptomatic MM patients with MRI. Focal marrow lesions 
were identified in 50% of patients, diffuse marrow replacement in 28%, a variegated pattern 
in 14%, and normal pattern in 8% of patients. Patients with diffuse pattern had a median 
www.intechopen.com
 
The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients 
 
149 
survival of 24 months, while it was longer than 50 months for the remaining patterns. It was 
shown in addition that patients with more than 7 focal lesions detected by MRI, had a worse 
outcome, while in contrast, the number of lesions on plain radiography did not contribute to 
prognosis (Walker et al, 2007). 
 
 
Fig. 2. Survival According to the Presence or Absence of Spontaneous Fractures. 
2.3 Prognostic factors related to tumor burden and growth fraction 
2.3.1 Beta-2-Microglobulin (β2Μ) 
Beta2-Microglobulin (ǃ2-Μ) is a subunit of the MHC class I molecule, associated with the 
outer membrane of almost all nucleated cells. High serum ǃ2-Μ levels are detected in 
patients with renal impairment, lymphoid malignancies and autoimmune disorders. In MM, 
ǃ2-Μ emerged as a predictor of survival in the late 1970s (Cassuto et al, 1978; Norfolk et al, 
1979). Its role in the initial staging and subsequent monitoring of monoclonal plasma cell 
disorders was studied (Garewal et al, 1984). However, it was not found helpful for 
monitoring MM disease course, since there are patients that relapse without a previous raise 
in ǃ2-Μ levels, while others show increases without any evidence of disease progression 
(Cuzick et al, 1990). Several stratification systems of ǃ2-Μ in combination with other disease 
parameters were afterwards proposed (Bataille et al, 1992). In 2005 the International Staging 
System (ISS) (Greip et al, 2005), based on clinical and laboratory data gathered on 11171 MM 
patients showed that the combination of ǃ2-Μ and albumin separated very efficiently 
prognostic subgroups. Median overall survival was 62, 44, and 29 months, for patients with 
ISS stages 1, 2, and 3 respectively. That system was simple and potent and replaced the 
Durie–Salmon staging system. ISS has important pitfalls; it is not disease specific and cannot 
separate the small subgroup of patients with a very limited survival, who will benefit from a 
different therapeutic approach (Rajkumar & Buadi, 2007). Attempts were therefore made to 
improve ISS prognostication by adding other variables (Table 1), namely LDH (Terpos et al, 
2010), serum free light chain ratio (Kyrtsonis et al, 2007b; Snozek et al, 2008) or cytogenetic 
abnormalities (Avet-Loiseau et al, 2009; Neben et al, 2010). 
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Study Model Results 
Terpos  
et al, 2010 
LDH ≥ or <300 
U/L within ISS 
groups 
ISS 1: 27,7% High LDH 7% 
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22 
Normal LDH 
93% 
76 
ISS 2: 38% High LDH 10% 11 
Normal LDH 
90% 
40 
ISS 3: 34,3% High LDH 12% 17 
Normal LDH 
88% 
27 
Neben  
et al, 2010 
Low risk: ISS 1 
and absence of 
t(4;14) or 
del17p13 
High Risk: ISS 
2/3 and t(4;14) or 
del17p13 
Int risk: All 
others 
Low: 42%  
5 years OS (%) 
72 
Intermediate: 
44% 
62 
High: 14% 41 
Snozek  
et al, 2008 
Presence of 
0,1,2,3 of sFLC 
abnormal, ǃ2Μ≥ 
3,5 g/dl, albumin 
3,5<g/dl 
0 factors: 12,6%  
5 years OS (%) 
41,5 
1 factor: 29,9% 32 
2 factors: 34,5% 24.5 
3 factors: 23,5% 13.4 
Kyrtsonis  
et al, 2007  
Low risk: sFLCR 
<median and ISS 
<3 
Int risk: Either 
sFLCR> median 
or ISS=3 
High risk: 
sFLCR> median 
and ISS=3 
Low: 29% 5 years OS (%) 90 
Intermediate: 
46% 
56 
High: 24% 24 
ISS: International Staging System, OS = overall survival, sFLCR = serum free light chain ratio,β2  
Μ: B2-microglobulin. 
Table 1. Risk-Stratification Models Attempting ISS Prognostication Improvement 
2.3.2 Lactate Dehydrogenase (LDH) 
Since the late 70s, the relationship between hematological malignancies and elevated LDH 
has been intensively studied (Talageri et al, 1977). In aggressive lymphoma patients, 
increased LDH was found linked to high tumor burden and turnover (Vezzoni MA et al, 
1983). Later on several investigators reported its prognostic value in MM patients 
(Simonsson et al, 1987; Barlogie et al, 1989), it was however not incorporated in any widely 
used staging system, although its ability to identify patients with an especially adverse 
outcome was shown (Dimopoulos et al, 1991; Kyrtsonis et al, 2007b). 
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2.3.3 Plasma cell proliferation 
Increased plasma cell proliferating potential determined by either labeling index, Ki-67 
immunostaining or flow cytometry predicts shorter survival.  
Plasma cell labeling index (PCLI) detects the percentage of cells in S-phase, by assessing 
bromodeoxyuridine uptake (Greipp et al, 1993). High PCLI was associated with both poor 
overall survival and progression-free survival (Boccadoro et al, 1989).  
Ki-67, a nuclear protein expressed in proliferating cells and absent from resting cells, 
constitutes an excellent marker of the neoplastic growth fraction. Increased Ki-67 
immunostaining on BM trephine biopsy specimens was found associated with shorter 
survival, hypodiploidy and identified an adverse prognostic group within ISS stage 1 
patients (Gastinne et al, 2010).  
Plasma cell proliferation can also be evaluated by flow cytometry using fluorescent dye 
which stains nucleic acids to detect the proportion of cells that actively double their DNA 
(Trendle et al, 1999). Actively proliferating cells’ immunophenotype was characterized and 
is CD45brightCD11apos (Robillard et al, 2005). 
2.4 Prognostic factors reflecting cell and microenvironment characteristics 
In this part, prognostic factors related to plasma cell appearance, secretion, expression, 
genetic lesions and interaction with the BM microenvironment will be presented. 
2.4.1 Plasma cell morphology 
In older studies, special attention was given to PCs morphology on BM smears (Fritz et al, 
1984). The presence of 2% or more plasmablasts in the plasma-cell population, was 
associated with a shorter survival (Greipp et al, 1998; Rajkumar et al, 1999). Plasmablasts 
were characterized as follows: fine reticular chromatin pattern in the nucleus; large nucleus 
less-abundant cytoplasm (Figure 3). In addition plasmablastic morphology was associated 
with increased presence of cytogenetic abnormalities. 
 
Fig. 3. Presence of Plasma Cells With Plasmablastic Morphology on BM Smears 
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2.4.2 Immunoglobulin heavy and light chain secretion 
The hallmark of MM is the secretion of monoclonal Ig by BM infiltrating PCs. Paraprotein 
can be detected by serum protein electrophoresis (SPEP) and immunofixation (IFE) and 
quantified nephelometrically or by SPEP densitometry. About 20% of patients secrete light 
chains only (LCO) that can be assessed by serum/urine IFE and precisely quantified by the 
serum free-light-chain (FLC) assay. Although serum monoclonal Ig quantification was one 
of Durie and Salmon staging system’s risk factors and was included in older prognostic 
algorithms (Bettini R, 1983), it was shown that MM aggressiveness or tumor load is not 
necessarily related to the amount of serum Ig heavy chain and subsequent stratification 
models did not retain it as a risk parameter (Kyrtsonis et al, 2009). However, paraprotein 
type was shown to influence survival; IgG patients enjoy the longest one, followed by IgA 
while LCO patients have the shortest (Drayson et al, 2006) 
With regard to the amount of Ig light chains secreted by malignant plasma cells, they were 
traditionally grossly evaluated by 24h proteinuria. In 2001, a new assay was introduced 
which allows precise quantification of serum free light chains (Bradwell et al, 2001; Bradwell 
et al, 2003). This highly sensitive method offered significant improvement in identifying and 
monitoring patients with oligo–secretory and LCO disease. In the next years, serum free 
light chain ratio (sFLCR) was shown a powerful and independent prognostic factor in newly 
diagnosed MM patients (Kyrtsonis et al, 2007; Snozek et al, 2008). Furthermore, the addition 
of sFLCR to factors of disease activity (LDH, ǃ2Μ, genetic abnormalities) provided powerful 
prognostic models (Kyrtsonis et al, 2007b; Kumar et al, 2010). 
Immunoassays using antibodies that target junctional epitopes between the heavy and light 
chains of each Ig molecule were recently manufactured for the analysis of Ig heavy 
chain/light chain (HLC) pairs (Hevylite™). These assays allow the precise quantification of 
the absolute value of the monoclonal IgGǋ, IgGǌ, IgAǋ and IgAǌ separately and of their 
deriving ratios (Keren 2009; Bradwell 2010). Preliminary results suggest that HLC and their 
ratios are prognostic with regard to time to treatment (Avet-Loiseau et al, 2009b) and overall 
survival (Koulieris et al, 2010; Ludwig et al, 2010). 
2.4.3 Plasma cell genetic abnormalities 
Chromosomal abnormalities may be evaluated by conventional karyotype, fluorescence in 
situ hybridization (FISH), comparative genomic hybridization, or by single nucleotide 
polymorphism (SNP). Classical cytogenetic analysis is rarely successful because of the low 
plasma cell proliferation rate; however, any chromosomal abnormality that is detected on 
standard cytogenetic analysis is associated with a worse outcome. Monosomy or partial 
deletion of chromosome 13 (del13q14) is a recurrent chromosomal aberration of adverse 
prognosis, observed in approximatively 50% of patients with abnormal karyotypes. The 
frequency of the aforementioned finding is much higher when evaluated by FISH that is 
more sensitive and significantly increases the proportion of patients with chromosomal 
aberrations. However, It seems that the adverse prognostic effect of 13q deletions, as 
detected by FISH, is related to other associated abnormalities, such as t(4;14) translocation 
and partial deletion on chromosome 17p and that patients who have only a chromosome 
13 deletion have the same prognosis as those who do not have this abnormality (Avet-
Loiseau et al, 2007; Kyrtsonis et al, 2010b). Specific translocations in the Ig heavy chain 
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region that are detected by FISH, such as t(4;14), deletion 17p13, and chromosome 1 
abnormalities, are associated with a poor prognosis and high risk, while standard-risk 
disease is defined by the presence of hyperdiploidy or t(11;14) (Fonseca et al, 2009; Avet-
Loiseau, 2010b). The reported adverse impact of other rarer translocations such as t(14;16) 
is still under investigation due to the absence of large testing series. Prognostic 
information provided by GEP and SNP studies recognizes abnormalities throughout the 
whole genome, but they require plasma cell purification and highly specified centers; they 
are not routinely available for clinical prognostic evaluation. 
2.4.4 plasma cell immunophenotype 
Multiparameter flow cytometry (MFC) immunophenotyping can recognize normal plasma 
cell (N-PC) from malignant ones (MPC) according to cell surface markers (CD19, CD38, 
CD45, CD56). It was shown that symptomatic MM patients who have more than 5% N-
PC/MPC at diagnosis present unique clinical, biological, and cytogenetic signature 
characterized by higher haemoglobin levels, less extended BM PC infiltration, lower 
paraprotein levels, and absence of high-risk cytogenetic abnormalities[t(4;14), t(14;16), 
del17p] (Paiva et al, 2009).  
The presence or absence of combined specific cell surface markers predicts outcome. Thus, 
positive staining for CD19 and CD28, as well as absence of CD117 detected on clonal PC 
were associated with significantly shorter survival (Bahlis et al, 2007; Paiva et al, 2011).  
Ploidy status evaluation, determination of the percentage of S-phase PC and stringent 
complete remission (sCR) categorization (Durie et al, 2006) are additional prognostic tools 
provided by MFC immunophenotype.  
2.4.5 Prognostic factors derived from plasma cells and microenvironment cells 
interactions 
The contribution of the medullary milieu to MM pathogenesis, was extensively studied 
during the past 30 years (Mitsiadis et al, 2006). Numerous cytokines and growth factors that 
sustain myeloma cell survival and proliferation are secreted upon plasma cells’ adhesion to 
stromal cells. The serum concentrations of some of these, namely soluble interleukin-6 
receptor (Pulki et al, 2006; Kyrtsonis et al, 2006) and soluble syndecan-1 (Seidel et al 2001, 
Kyrtsonis et al, 2004), are strongly prognostic for adverse survival.  
The formation of new vessels and interactions between plasma cells and osteoclasts (OCs) 
are other important microenvironment processes accompanied by the secretion of cytokines 
and soluble factors that may also constitute prognostic factors. Bone marrow neo-
vascularization is required to support neoplastic cells’ metabolic requirements. The 
microvessel density correlates with disease stage and prognosis (Vacca et al, 1994; Kumar et 
al, 2004). Evolution from monoclonal gammopathy of unknown significance to MM, has 
been found associated with loss of marrow angiogenesis inhibitory activity (Kumar et al, 
2004b). Myeloma and stromal cells produce angiogenic growth factors such as vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) that may 
account, in part, for the increased microvessel density observed in the BM. Both factors are 
specific endothelial cell mitogens and their serum levels were found in correlation with 
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disease activity markers in MM patients (Sezer et al, 2001). VEGF also induces proliferation 
and triggers migration of MM cells by increasing vascular permeability (Podar et al, 2001). 
In addition, hepatocyte growth factor (HGF) stimulates epithelial cells’ growth, further 
induces blood vessel formation and promotes osteoclasts formation and activation; high 
serum HGF levels predicted poor response to therapy and survival (Di Raimondo et al, 
2000). The process of angiogenesis in MM is not yet fully elucidated; it is thought that 
imbalance of angiogenic regulators including angiopoietins along with other known and 
unknown factors are additionally involved. Increased serum Angiopoietin-2 or low 
Angiopoietin-1/Angiopoietin-2 ratio were recently found correlated with markers of disease 
activity and overall survival (Joshi et al, 2011; Terpos et al, 2011). Moreover, inhibition of 
neovascularization offers promising therapeutical implications and such mechanisms 
account in part for the improved anti-myeloma activity of new drugs. 
Osteolyses in MM is caused by OCs proliferating in bony areas adjacent to myeloma cells. 
This promiscuity favours both cell types to secrete soluble factors sustaining one each 
other’s activity. The main stimulator of OC formation is a member of the TNF family, 
namely the receptor activator of NF-kappaB ligand (RANKL). RANKL binds to the RANK 
receptor, on osteoclast progenitors, inducing OC differentiation and maturation while on the 
contrary, osteoprotegerin (OPG), a natural decoy receptor, blocks RANKL/RANK ligation. 
In addition, OCs are further regulated by other factors, including TNF, IL-1, IL-6, MIP-1a, 
while at the same time osteoblast inactivation is induced by IL-3, IL-7 and DKK1. 
RANKL/OPG ratio, MIP-1a, and DKK1 serum levels were all found of prognostic 
significance (Terpos et al, 2003a & b; Gavriatopoulou et al, 2009). 
3. Prognostic factors of response to treatment 
Treatment options for patients with MM at diagnosis and in relapse have dramatically 
increased. High dose treatment (HDT) with autologous stem cell transplantation (ASCT), 
thalidomide, lenalidomide, and bortezomib, introduced in the past 2 decades, resulted in 
improved outcomes and duration of response (Kumar et al, 2008; Lonial S, 2010). In 
addition, the depth of response seen with these modalities was never observed before, 
opening horizons for eventual cure. The aforementioned treatments are able to overcome 
the impact of well-known adverse prognostic factors and risk-stratification models, 
rendering the establishment of newer, more appropriate ones, mandatory.  
3.1 Quality of response and response duration 
Achieving complete response (CR) is an important goal based on the general principle that 
focuses in reaching the lowest tumor burden possible, in an intend to cure. In numerous 
studies, it was shown that the “quality” of response positively influenced both event free 
survival (EFS) and overall survival (OS). As “qualitative” responses, very good partial 
responses (VGPR), near complete responses (nCR) and CR (Blade et al, 1998), were included. 
In an attempt to better define deeper CR, stringent CR was introduced as a new category 
in the recent “uniform international response criteria”, concerning patients that, in 
addition to the previous criteria for CR (Blade et al, 1998), also presented normalization of 
free light chain ratio (FLCR) and absence of clonal cells as determined either by bone 
marrow immunfluoresence or immunohistochemistry (Durie et al, 2006). However the 
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importance of FLCR in this context remains controversial. An important limitation of the 
definition is that “abnormal” FLCR has not been well defined. FLCR assesses both 
eventual increase of involved FLC (iFLC) and suppression of the polyclonal one of the 
same class (pFLC); in addition normal values for kappa and lambda FLCs are not exactly 
the same. Setting the appropriate normal range for FLCR in general or cutoff for the “high 
FLCR” group has been proven a challenging task. The mostly widely accepted reference 
range for FLCR is 0.26-1.65. In our experience, the use of “high” and “low” FLCR with 
different cutoff values for kappa and lambda patients was more appropriate; we therefore 
used the median value of each group separately as cut – off (Kyrtsonis et al, 2007; 
Kyrtsonis et al 2008). Indeed, the median value changes from a patients’ series to another. 
An international consensus agreement defining appropriate normal values is urgently 
needed. We also believe that the choice of a “high” and “low” cutoff will resolve to some 
extend, the problem of the so called “discordant” presence of abnormal FLCR with 
normal IFE (de Larrea CF et al, 2009; Singal et al, 2009), given that absence of minimal 
residual disease (MRD) does not necessarily mean absence of polyclonal Ig depression 
involving pFLC and resulting in an abnormal FLCR when using the proposed “lower than 
0.26 or higher than 1.65” range, while it would have been “low” FLCR if our system was 
used. Eventually because of this limitation, although it has been four years since the 
introduction of the sCR entity, the impact of its achievement has not been yet evaluated in 
large clinical trials.  
Multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) are very 
sensitive methods for MRD evaluation (Liu H et al, 2008; Paiva et al, 2011; Corradini et al, 
2003; Martínez-Sanchez et al, 2008). A recent study showed that achievement of 
immunophenotypic response leads to better response duration and OS than CR and sCR. 
The inclusion of these methods for response evaluation was thus proposed. They are 
however less widely available. 
3.2 Prognostic factors for high dose treatment and autologous transplant 
With conventional treatment CR did not exceed 5% while few patients were primary 
resistant, the median overall survival (OS) being 3 years. The addition of HDT with 
autologous bone marrow or stem cell rescue increased the CR rate up to 30-40% (Attal et al, 
1992; Lenhoff et al, 2000; Barlogie et al, 2004) and median OS to 4-5 years. However, 
although HDT with ASCT may overcome the adverse prognosis of a significant number of 
classical adverse PFs, unsatisfactory response duration was observed after high dose 
treatment and bone marrow transplantation or stem cell rescue in patients with partial or 
complete deletions of chromosome 13 by conventional cytogenetics (Tricot et al, 1995), 
t(4;14)(p16;q32), t(14;16)(q32;q23) and 17p13 deletions (Gertz et al, 2005; Avet-Loiseau, 2007), 
deletions and gains of chromosome 1p21 (Chang et al, 2005) or its associated gene CKS1B 
amplification (Chang et al, 2006). However, a recent retrospective study showed that only 
HDT with ASCT overcome the adverse prognosis conferred by high FLCR, while the same 
was not true for novel agents (Maltezas et al, 2011). 
An interesting observation was that, symptomatic MM patients with more than 5% normal BM 
PCs displayed a greater response rate to HDT/ASCT; The CR rate was 64% versus 33% in the 
rest with significantly longer progression free and overall survival rates (Paiva et al, 2010). 
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3.3 Prognostic factors for new agents 
Over the last years, new therapeutic agents, such as thalidomide, lenalidomide and 
bortezomib have become approved and available for the treatment of MM (Engelhardt et al, 
2006; Pangalis et al, 2006). When they are given alone or in combination with corticosteroids 
or other agents, they produce high response rates including a considerable percentage of 
complete remissions (CR) or near CR (nCR). The latter is probably due to their capacity to 
overcome some markers of adverse prognosis (Table 2). 
 
Marker ASCT 
New Agent 
Comments 
Thalidomide Lenalidomide Bortezomib
Age S S O O  
PS Ineligible S S S  
LC MM O O O O  
 Hb O S O O  
 Cr O S O O  
 Ca U S O O  
 LDH S S S S  
FLC/FLCR O S S S  
sIL-6R U U U U  
s-syndecan-1 U U U U  
VEGF U S U U  
HGF U S U U  
PCLI S S S U  
Hypodiploidy U U S U  
Del13q/Δ13c S S S O  
t(4;14) S S S O  
del 17p13 S S S O 
Conflicting 
data for 
bortezomib  
1p21 lesions S S S O  
CKS1B amp S U U O  
S: sustained, O: overcome, U: unknown, c: By conventional cytogenetics, 
Table 2. Ability of Novel Agents To Overcome Some Markers Of Adverse Prognosis. 
3.3.1 Thalidomide 
The introduction of thalidomide in MM therapeutics was revolutionary because it 
constituted the first treatment able to act both on myeloma and microenvironmental cells. Its 
mechanism of action includes direct inhibition of malignant plasmacytes via 
immunomodulation of T-cells and enhancement of NK-cells (Davies et al, 2009). It also 
affects BM stromal cells, creating a hostile microenvironment (Mitsiades et al, 2002). The last 
is mediated through reduction of expression of angiogenic factors (IL-6, TNF-a, bFGF, 
VEGF) via gene downregulation in BM endothelial cells (Vacca et al, 2005).  
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The first important study on thalidomide as a single agent (Singal et al, 1999), showed a 
response rate of 32% in relapsed-refractory MM patients. Subsequently other investigators 
confirmed thalidomide efficacy as a single agent or in combination with dexamethasone, 
chemotherapy or other new agents (Rajkumar et al, 2000; Juliusson et al, 2000; Blade et al, 
2001). However, thalidomide does not seem able to overcome established adverse 
prognostic factors such as advanced stage, age ≥ 65 years, abnormal karyotype, increased 
LDH and ǃ2M, del q13/Δ13, hypodiploidy, t(4;14), t(14;16), 17p13 deletions, chromosome 1 
abnormalities, nor that of increased VEGF and HGF levels (Mileshkin et al, 2007); however it 
was shown able to reverse the poor prognosis associated with cyclin-D1 negativity and 
fibroblast growth factor-3 positivity (Kelly et al, 2009). The adverse impact of PCLI was not 
overcome by Thalidomide (Kapoor et al, 2009). 
3.3.2 Lenalidomide 
Lenalidomide is an immunomodulatory drug. In combination with dexamethasone it 
constitutes an effective treatment option for most patients with relapse/refractory MM. In 
myeloma cells, lenalidomide inhibits cell growth, promotes apoptosis and blocks their 
adhesion to stromal cells in the BM milieu (Richardson et al, 2002). In stromal cells, 
lenalidomide reduces the expression of angiogenic factors and several additional factors that 
support plasma cell growth (Dredge et al, 2002). In addition, lenalidomide stimulates T cells 
and natural killer cells (Marriot et al, 2002).It may be beneficial regardless of patient age, 
disease stage and renal function, although the starting dose of lenalidomide should be 
adjusted for renal impairment and cytopenias (Dimopoulos et al, 2011). It was relatively 
recently (early 2008) approved in Europe for the treatment of relapse/refractory patients 
and there are at present only few studies on its effectiveness in the presence of cytogenetic 
findings conferring adverse prognosis. A study on 100 newly diagnosed patients that 
received front-line lenalidomide/dexamethasone showed that patients with high risk MM 
defined by the presence of hypodiploidy, del(13q) by metaphase cytogenetics, del(17p), 
t(4;14), or t(14;16) and high plasma cell labeling index, had a shorter progression-free 
survival compared to standard-risk patients (Kapoor et al, 2009). In addition it was shown 
unable to overcome the adverse prognosis of chromosome 1 abnormalities (Chang et al, 
2010). 
3.3.3 Bortezomib 
Bortezomib (Velcade®) is a reversible inhibitor of the chymotryptic component of the 26S 
proteasome. Thus, by inhibiting the proteasome, it inactivates key proteins implicated in cell 
growth and function such as nuclear factor kappa B (NF-ǋB), leading to the inhibition of 
cytokines and growth factors, immunoreceptors, adhesion molecules, transcription factors 
and to the induction of apoptosis. In addition, angiogenesis is downregulated through 
inhibition of VEGF and IL-6, which are produced by vascular endothelial cells. In addition, 
normalization of the angiopoietin-1/angiopoietin-2 ratio was shown a surrogate marker of 
response to bortezomib in relapsed/refractory MM patients (Anargyrou et al, 2008). 
Furthermore, indirect anti-tumor effects resulting from gene silencing of RANKL have been 
reported. The drug has an osteoblast activating effect by reducing serum dickkopf-1, 
resulting in an increase of bone-type alkaline phosphatase (Terpos et al, 2006).  
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In Europe, it has been licensed only for the treatment of relapsed/refractory MM patients or 
those with previously untreated MM, who are not eligible for high-dose chemotherapy with 
ASCT, in combination with melphalan and prednisone, while in the US there are no 
restrictions. 
It was shown able to overcome the adverse effect of deleterious genetic aberrations (13q 
deletions, t(4;14), amplification CKS1B (Chang et al, 2007; Jannagath, 2007; Sagaster, 2007). 
Drug effectiveness in patients with del(17p) is controversial (Avet-Loiseau et al, 2010b); 
patients may respond but rapidly relapse. Some subanalyses and prospective studies 
suggest that up-front bortezomib-based treatment followed by HDT/ASCT and 
reinductions with bortezomib-lenalidomide-dexamethasone combinations may benefit high-
risk patients with t(4;14) or del(17p). Nevertheless a subset of patients will still present early 
death (Avet-Loiseau, 2010).  
4. Prognostic factors related to specific disease manifestations 
The prediction of particularly morbid MM manifestations in order to avoid them, if possible, 
would have been of special interest. Unfortunately, although there are a number of markers 
that reflect specific manifestations, almost none predict their acute onset. For example, bone 
disease is more extended when increased concentrations of cytokines and soluble factors 
involved in bone metabolism are observed, but this is not enough to predict spontaneous 
fractures. In the same way, patients with polyclonal hypogammaglobulinaemia are more 
prone to infections but the presence of depressed polyclonal antibodies is not a strong 
enough predictor of infection in order to administer antibiotics. The most “predictable” 
disease manifestation is renal failure and evidences of genetic predisposition for peripheral 
neuropathy are emerging (Corthals et al, 2011). 
4.1 Renal failure 
Rapidly increasing sFLCs, observed while monitoring patients, predict imminent renal 
failure. Approximately 40% of MM patients have renal impairment at clinical presentation 
and 5-10% will require haemodialysis because of acute renal failure from cast nephropathy. 
Since the pre-renal load of sFLCs is the direct cause of renal damage, it is logical to monitor 
for rising concentrations on a regular basis, so that acute renal failure during disease relapse 
can be avoided by early treatment initiation (Hutchison et al, 2007).  
5. Conclusion 
In current clinical practice, MM patients’ workout at diagnosis, automatically include 
prognostic factors such as CBC, creatinine, albumin, ǃ2Μ, LDH, 24 hours proteinuria, SPE, 
IFE and quantitative Ig and FLC measurements (with FLCR calculation), bone survey, bone 
marrow aspiration and biopsy with conventional karyotype. Information provided allows 
staging as well as additional prognostication based on LDH and FLC/FLCR values, thus 
helping treatment choices. However, if the decision to make is between thalidomide- and 
Bortezomib- containing regimens, FISH studies, eventually revealing high risk 
translocations, are useful. Therefore, they should also be routinely performed. Indeed, other 
more sensitive and patients’ specific prognostic information can possibly be provided by 
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GEP and SNP studies but, for the time being these highly specified techniques concern 
research and are not available for clinical purposes. 
After treatment, best response depth estimation is important. The introduction of stringent 
CR improves response evaluation but a more rigorous definition is needed and results of 
large clinical trials on the impact of sCR achievement are awaited. Possible additional 
information provided by multiparameter flow cytometry should be explored, if available. 
The question raised at that time is weather some kind of maintenance would make 
remission last longer. 
During follow-up of MM patients in remission and plateau phase, FLC monitoring allows 
prevention of renal damage and early recognition of relapse. 
At the time of relapse, PFs are once again needed to predict outcome; practically, the same 
that were determined at diagnosis, should be tested. 
In conclusion, prognostic factors and systems have evolved during the past years. They 
allow a better disease management and contribute to the improvement observed with 
regard to survival. Unfortunately, there is still a proportion of patients with suboptimal 
outcomes and disease remains incurable at present. 
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